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Abstract Liver X receptors (LXRK and LXRL) are nuclear
receptors, which are important regulators of cholesterol and
lipid metabolism. LXRs control genes involved in choles-
terol e¥ux in macrophages, bile acid synthesis in liver and in-
testinal cholesterol absorption. LXRs also regulate genes par-
ticipating in lipogenesis. To determine whether the activation
of LXR promotes or inhibits development of atherosclerosis,
T-0901317, a synthetic LXR ligand, was administered to low
density lipoprotein receptor (LDLR)3=3 mice. T-0901317 sig-
ni¢cantly reduced the atherosclerotic lesions in LDLR3=3 mice
without a¡ecting plasma total cholesterol levels. This anti-ath-
erogenic e¡ect correlated with the plasma concentration of
T-0901317, but not with high density lipoprotein cholesterol,
which was increased by T-0901317. In addition, we observed
that T-0901317 increased expression of ATP binding cassette
A1 in the lesions in LDLR3=3 mice as well as in mouse peri-
toneal macrophages. T-0901317 also signi¢cantly induced cho-
lesterol e¥ux activity in peritoneal macrophages. These results
suggest that LXR ligands may be useful therapeutic agents for
the treatment of atherosclerosis.
, 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
Key words: Liver X receptor; Nuclear receptor;
ATP binding cassette A1; Cholesterol e¥ux;
Macrophage; Atherosclerosis
1. Introduction
Liver X receptors (LXRs), LXRK and LXRL, are members
of the nuclear receptor superfamily and are involved in regu-
lation of cholesterol and lipid metabolism. LXRs bind to
DNA as obligate heterodimers with retinoid X receptors
and are activated by oxysterols [1,2].
In the liver, LXRs contribute to regulation of the gene
encoding cholesterol 7K-hydroxylase, the rate-limiting enzyme
in conversion of cholesterol to bile acids [3]. In intestine,
LXRs increase expression of ATP binding cassette (ABC)
A1 and ABCG1, which are involved in intestinal cholesterol
absorption [4^6]. ABCA1 also plays an important role in
apolipoprotein (apo) A-I-dependent cholesterol e¥ux in mac-
rophages [7]. The importance of ABCA1 and reverse choles-
terol transport is highlighted by the linking of Tangier disease,
a genetic disorder of high density lipoprotein (HDL) de¢-
ciency, with a mutation in the gene encoding ABCA1 [8^
10]. Patients with Tangier disease exhibit reduction in plasma
HDL levels and massive accumulation of cholesterol in the
peripheral tissues, and are at increased risk for atherosclerosis
[11^14].
Recent studies have also revealed that LXRs are involved in
the regulation of triglyceride metabolism [15,16]. It has been
reported that a synthetic LXR ligand increased expression of
genes participating in lipogenesis such as sterol response ele-
ment binding protein 1c (SREBP-1c), fatty acid synthetase
(FAS), stearoyl CoA desaturase 1 (SCD-1) and lipoprotein
lipase and induced hypertriglyceridemia in mice [17,18].
These ¢ndings raised the question of whether the activation
of LXRs promotes or inhibits atherosclerosis. In the present
study, we administered T-0901317, a synthetic LXR ligand,
to atherogenic diet fed low density lipoprotein receptor
(LDLR)3=3 mice, an animal model of progressive atheroscle-
rosis. The e¡ect of T-0901317 on lipid pro¢les, extent of ath-
erosclerosis, and gene expression was investigated.
2. Materials and methods
2.1. Animals and diet
Male LDLR3=3 and C57BL/6 mice were obtained from Crea Ja-
pan, Inc. The LDLR3=3 mice were fed an atherogenic diet (1.25%
cholesterol, 7.5% cocoa butter and 0.5% sodium cholate). The LXR
ligand T-0901317 at doses of 3 and 10 mg/kg was orally administered
daily in propylene glycol/Tween 80 (4/1) formulation to LDLR3=3
mice for 8 weeks. Blood was drawn and total cholesterol (TC) and
triglyceride (TG) levels were determined. At week 8, the mice were
sacri¢ced, blood was obtained and tissues were collected for further
analysis.
2.2. Isolation of mouse peritoneal macrophages
Thioglycolate-elicited peritoneal macrophages were isolated from
the C57BL/6 mice 4 days after peritoneal injection of thioglycolate
broth medium [19].
2.3. Lipoproteins and their modi¢cation
Human LDL (d=1.019^1.063) and HDL3 (d=1.125^1.21) were
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isolated by sequential ultracentrifugation from the plasma obtained
after overnight fasting of normolipidemic subjects who had given their
consent. Acetyl-LDL was prepared by chemical modi¢cation of LDL
with acetic anhydride [20].
2.4. RNA isolation and analysis of gene expression by real-time
quantitative PCR
Total RNA from the mouse peritoneal macrophages was isolated
using TRIzol Reagent (Invitrogen) according to the manufacturer’s
protocol. To generate cDNA, 1 Wg of total RNA was used with the
oligo dT primer following the protocol for First Strand cDNA Syn-
thesis kit (Amersham Bioscience). Real-time quantitative PCR analy-
sis was performed using the ABI Prism 7700 system (Applied Biosys-
tems). The level of the ABCA1 mRNA expression was normalized to
cyclophilin mRNA expression level. The sequences of forward prim-
ers, reverse primers and TaqMan probes, respectively, were as
follows: ABCA1: GCTCTCAGGTGGGATGCAG, GGCTCGTCC-
AGAATGACAAC, FAM-CTTGGCCTTCGTGGGTGGATCC-TA-




Mouse peritoneal macrophages were labeled with 0.2 WCi/ml
[14C]cholesterol and 50 Wg/ml acetyl-LDL for 48 h. Labeled cells
were washed, and e¥ux was initiated in medium with or without
200 Wg/ml HDL in the absence or presence of T-0901317. Radioac-
tivity of [14C]cholesterol in medium was monitored for 48 h.
2.6. Lipid and lipoprotein analyses
Plasma TC and TG levels were determined using commercial kits
(Wako Pure Chemical Industries, Ltd.). Lipoprotein pro¢les were
analyzed with high performance liquid chromatography (HPLC)
[21].
2.7. Preparation of histological sections and analysis of atherosclerosis
Preparation of histological sections from the aortic root was essen-
tially according to a technique as described by Paigen et al. [22] and
modi¢ed by Calleja et al. [23]. The heart was ¢xed in periodate lysine
paraformaldehyde ¢xative at 4‡C for 24 h and para⁄n-embedded.
The atherosclerotic lesion area of Elastica Masson-stained sections
was determined with image analysis software (Qwin, Leica AG).
The results are represented as the average of four sections each sep-
arated by 100 Wm.
Macrophages were detected with monoclonal rat anti-mouse anti-
body MOMA-2 (Biosource International). Tissue sections were incu-
bated in Tris-bu¡ered saline containing 0.1% trypsin and 0.1% CaCl2
for 30 min at room temperature to retrieve the antigenicity. Endoge-
nous peroxidase activity was quenched by incubation with 3% H2O2.
The sections were incubated with MOMA-2 diluted 1:10 at 4‡C over-
night. Then, the sections were incubated with biotinylated rabbit anti-
rat IgG (1:500, Dako Japan Co., Ltd.) for 30 min at room temper-
ature. After horseradish peroxidase-conjugated streptavidin (Nichirei
Corporation) was applied to the sections, antibody binding was visu-
alized with diaminobenzidine (Dako Japan Co., Ltd.). The sections
were counter-stained with methyl green.
Expression of ABCA1 was determined by polyclonal anti-ABCA1
antibody (Novus Biologicals, Inc.). Tissue sections were incubated
with anti-ABCA1 antibody diluted 1:500 at 4‡C overnight. Then
the sections were incubated with biotinylated donkey anti-rabbit
IgG (1:500, Amersham Bioscience) for 30 min at room temperature.
Immunoactivities were detected as well as MOMA-2.
2.8. Determination of plasma concentration of T-0901317
Plasma concentrations of T-0901317 were determined using the
HPLC system (LC10 System, Shimazu Corporation) with a Luna
5W C18 column (Phenomenex).
2.9. Statistical analysis
Values are represented as meanVS.E.M. Statistical signi¢cance
from the control was assessed using Dunnett’s multiple compari-
son test and analysis of variance (ANOVA). A di¡erence was con-
sidered to be statistically signi¢cant when the P-value was less than
0.05.
3. Results
3.1. Expression of ABCA1 mRNA and cholesterol e¥ux
Treatment of mouse peritoneal macrophages with
T-0901317 resulted in a dramatic increase in ABCA1 mRNA
expression (Fig. 1). T-0901317 was signi¢cantly more e¡ective
than HDL3 in inducing cholesterol e¥ux. ApoA-I-dependent
cholesterol e¥ux was also induced by T-0901317 (data not
shown).
3.2. Plasma lipid and lipoprotein pro¢les
LDLR3=3 mice were orally administered T-0901317 at
doses of 3 and 10 mg/kg for 8 weeks. The atherogenic diet
elevated plasma TC levels from approximately 300 to 2400
mg/dl and decreased HDL-C levels from approximately 100
to 30 mg/dl in the control group at week 1 (Table 1).
Treatment with T-0901317 had no in£uence on plasma TC
levels. T-0901317 signi¢cantly increased chylomicron-choles-
terol levels at weeks 1 and 5, but these completely recovered
to the same levels as the control group by week 8. However,
treatment with T-0901317 at 10 mg/kg signi¢cantly decreased
very low density lipoprotein (VLDL)+LDL-C (exposure:
20 943.1^17 524.7 mg/week/dl). On the other hand, HDL-C
Fig. 1. Induction of ABCA1 mRNA expression and cholesterol ef-
£ux in mouse peritoneal macrophages by T-0901317. A: ABCA1
mRNA assay. Mouse peritoneal macrophages were treated for 24 h
in the absence or presence of 0.01, 0.1, or 1 WM of the LXR ligand
T-0901317, and total RNA was isolated. ABCA1 mRNA expression
levels were determined by real-time quantitative PCR and normal-
ized to cyclophilin. Data are presented as mRNA expression relative
to the vehicle control. B: Cholesterol e¥ux assay. Mouse peritoneal
macrophages were incubated with acetyl-LDL for 48 h. Labeled
cells were washed, and e¥ux was initiated in medium with or with-
out 200 Wg/ml HDL in the absence or presence of T-0901317. Ra-
dioactivity of [14C]cholesterol in the medium was monitored for
48 h.
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Fig. 2. Inhibitory e¡ect of T-0901317 on the development of atherosclerotic lesions in LDLR3=3 mice. A,B: Representative Elastica Masson
staining of aortic root lesions from atherogenic diet-fed LDLR3=3 mice after administration of the LXR ligand T-0901317 for 8 weeks.
C: Quantitative analysis of atherosclerosis lesion areas. MeanVS.E.M. were: control, 20 1615V 23 346 Wm2 (n=9); T-0901317 3 mg/kg,
86 899V 17 271 Wm2 (n=8); T-0901317 10 mg/kg, 58 667V 9835 Wm2 (n=8). *P6 0.05, as compared with the control group using Dunnett’s
multiple comparison test.
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levels were increased by T-0901317 in a dose-dependent man-
ner (exposure: 301.3, 543.0 and 667.9 mg/week/dl for control,
3 and 10 mg/kg, respectively). TG elevation by the treatment
with T-0901317 was observed at week 1, but gradually de-
clined during the administration period and completely recov-
ered to the same level as the control group by week 8.
3.3. Analysis of atherosclerosis lesions
The atherosclerotic lesions were dominantly composed of
foamed macrophages. Treatment with T-0901317 at 3 and
10 mg/kg dramatically inhibited the development of athero-
sclerosis compared with the control group (57 and 71% re-
duction, respectively; Fig. 2). We also analyzed expres-
sion of ABCA1 protein in the lesions using anti-ABCA1
antibody (Fig. 3). The immunostaining of aortic root sec-
tions treated with T-0901317 revealed that signi¢cant expres-
sion of ABCA1 protein was co-localized with the macro-
phages. Plasma concentrations of T-0901317 were measured
by use of HPLC. There was a negative correlation between
mean lesion area and plasma concentration of T-0901317, but
no correlation between mean lesion area and HDL-C level
(Fig. 4).
Table 1
E¡ect of T-0901317 on plasma lipid and lipoprotein levels in LDL receptor-de¢cient mice
TC (mg/dl) Chylomicron-C (mg/dl) VLDL+LDL-C (mg/dl) HDL-C (mg/dl) Triglycerides (mg/dl)
Vehicle (n=9)
Week 0 276.5V 7.2 0.2 V 0.2 170.1V 6.4 106.2V 1.8 195.0V 11.5
Week 1 2 419.9V 143.4 88.2V 19.1 2 300.1V 134.8 31.6V 3.0 300.2V 35.7
Week 5 3 741.0V 241.8 225.3V 49.6 3 477.1V 214.0 38.7V 6.9 404.1V 80.2
Week 8 1 981.2V 60.3 0.0 V 0.0 1 958.6V 60.1 22.6V 1.8 95.8V 4.4
Exposure 22 253.4V 887.0 1 009.2V 213.1 20 943.1V 784.7 301.3V 30.3 2 405.9V 334.9
T-0901317 3 mg/kg (n=8)
Week 0 273.6V 7.5 5.3 V 5.3 172.0V 10.4 96.3V 3.5 208.0V 7.0
Week 1 2 911.4V 115.9 541.1V 69.7* 2 290.8V 92.5 79.5V 4.9* 2 811.4V 460.6*
Week 5 3 793.3V 194.1 463.7V 66.9* 3 263.0V 137.6 66.6V 5.6* 749.3V 135.5
Week 8 1 882.5V 94.7 0.9 V 0.9 1 840.4V 92.7 42.1V 3.3* 140.3V 27.6
Exposure 23 515.5V 855.1 2 979.7V 294.4* 19 993.9V 642.8 543.0V 27.4* 9 965.3V 1 330.8*
T-0901317 10 mg/kg (n=8)
Week 0 277.8V 8.0 0.0 V 0.0 177.5V 6.6 100.2V 3.3 199.7V 12.4
Week 1 2 934.9V 363.6 754.9V 112.2* 2 090.1V 250.8 89.9V 12.2* 6 347.4V 919.8*
Week 5 3 428.9V 242.4 502.0V 97.4* 2 843.7V 144.2 83.3V 10.7* 1 077.1V 160.1*
Week 8 1 573.0V 82.1 0.0 V 0.0 1 505.3V 82.3* 67.7V 5.6* 137.7V 14.1
Exposure 21 836.8V 1 273.6 3 644.2V 424.1* 17 524.7V 849.8* 667.9V 46.6* 19 944.7V 1 976.8*
Data are represented as meanVS.E.M. (n=8^9). The data are also expressed as ‘exposure’ during the 8-week treatment phase. *P6 0.05, as
compared with the vehicle group using ANOVA and Dunnett’s multiple comparison test.
Fig. 3. Expression of ABCA1 protein within macrophages in atherosclerotic lesions from LDLR3=3 mice. A,B: Representative immunostaining
of aortic root lesions from atherogenic diet-fed LDLR3=3 mice with anti-ABCA1 and anti-MOMA-2 (macrophage) after administration of the
LXR ligand T-0901317 for 8 weeks.
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4. Discussion
Recent studies have identi¢ed LXRs as important regula-
tors of cholesterol and lipid metabolism. It has been reported
that LXR ligands increase expression of ABCA1 and induce
apoA-I-dependent cholesterol e¥ux [7]. However, LXR li-
gands have also been shown to induce expression of genes
involved in lipogenesis and elevate plasma TG levels [15,16].
These ¢ndings raised the question of whether the activation of
LXRs promotes or inhibits atherosclerosis. In the present
study, we demonstrated that T-0901317, a synthetic LXR li-
gand, dramatically inhibited the development of atherosclero-
sis in LDLR3=3 mice fed an atherogenic diet.
We also observed that T-0901317 signi¢cantly increased
HDL-C, although it did not change plasma TC. Another
study indicated that the liver is a major site of HDL assembly
[24]. Recent reports identifying mutations on the ABCA1 gene
in patients with Tangier disease raised the possibility that
ABCA1 participates in the synthesis of HDL [4^6]. However,
T-0901317 did not change ABCA1 mRNA expression in liver
(data not shown). This observation implies that other gene(s)
regulated by LXRs in liver may participate in HDL increase.
T-0901317 also increased plasma TG with the major lipopro-
tein peaks being VLDL and chylomicron, which is a TG-rich
lipoprotein secreted from intestine. Although other studies
investigated the e¡ect of LXR agonists only in liver [15,16],
our ¢nding suggests that the action of an LXR agonist in
intestine also contributed to TG elevation. However, TG ele-
vation gradually declined during the administration period
and completely recovered to the same level as the control
group. SREBP-1c, FAS and SCD-1 mRNA levels in liver
were hardly changed at week 8 (data not shown). Continuous
increase in liver TG content might induce other regulatory
pathway(s) for TG synthesis and metabolism, and as a result
repress gene expression via LXRs.
The alteration of lipid pro¢les raised the question of
whether T-0901317 a¡ected macrophages in atherosclerotic
lesions directly or indirectly. Interestingly, multiple regression
analysis demonstrated that the extent of atherosclerosis
negatively correlated with the plasma concentration of
T-0901317, but not with that of HDL-C. Thus, the alteration
of lipid pro¢les may minimally contribute to the anti-athero-
genic e¡ect. T-0901317 also induced expression of ABCA1
protein in the lesions, which co-localized with macrophages.
In addition, T-0901317 signi¢cantly increased ABCA1 mRNA
and enhanced HDL3-dependent cholesterol e¥ux in vitro.
These results strongly suggest that T-0901317 directly a¡ected
macrophages, enhanced cholesterol e¥ux via up-regulation of
ABCA1 and resulted in signi¢cant prevention of atheroscle-
rosis.
Cholesterol accumulation in macrophages is thought to be
mediated primarily by uptake of modi¢ed LDL via scavenger
receptors, scavenger receptor class A and CD36 being key
players [25,26]. Unlike LDL receptors, scavenger receptors
are not subject to negative regulation by cellular cholesterol.
Thus, maintenance of cholesterol homeostasis under condi-
tions of constitutive uptake of modi¢ed lipoproteins requires
activation of the cholesterol e¥ux pathway. Other studies
show that oxysterols, which exist abundantly in macrophages
within atherosclerotic lesions, are the physiological ligands for
LXRs [1,27,28]. In this study, we proved that an LXR agonist
has a potent anti-atherogenic e¡ect, showing direct induction
of cholesterol e¥ux in macrophages. Recently Tangirala et al.
[19] also demonstrated that LXRs in macrophages play a
protective role in the development of atherosclerosis in a
bone marrow transplantation study using LXR-de¢cient
mice. These observations strongly support the idea that
LXR ligands could be promising as therapeutic agents for
the treatment of atherosclerosis.
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